This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Clinical and Pathologic Studies in Neuroendocrine Tumors

This study has been terminated.
(not known)
Information provided by:
Stanford University Identifier:
First received: April 9, 2008
Last updated: February 26, 2010
Last verified: February 2010
This research involves the study of neuroendocrine tumors in order to better understand how the disease grows and spreads. This study requires will use tissue collected from from biopsies performed during your regular medical care (i.e. tissue leftover after your diagnosis has been made) and/or blood and urine samples. This study may lead to the development of special materials that could be used, in the future, to treat neuroendocrine tumors or to follow the response of neuroendocrine tumors to treatment

Condition Intervention
Carcinoid Tumor Neuroendocrine Tumors Procedure: blood sample draw Procedure: urine sample

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Clinical and Pathologic Studies in Neuroendocrine Tumors

Resource links provided by NLM:

Further study details as provided by Stanford University:

Biospecimen Retention:   Samples Without DNA
biopsy of tumor, blood sample and/or urine samples.

Estimated Enrollment: 200
Study Start Date: July 2007
Estimated Study Completion Date: June 2008
Estimated Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
neuroendocrine tumor patients

Inclusion Criteria:- Patients are eligible if they have a histologically proven neuroendocrine tumor and are 18 years of age or older

- Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:None

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00657332

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Principal Investigator: George Albert Fisher M.D. Ph.D. Stanford University
  More Information

Responsible Party: George Albert Fisher M.D. Ph.D., Stanford University School of Medicine Identifier: NCT00657332     History of Changes
Other Study ID Numbers: SU-12102007-931
Study First Received: April 9, 2008
Last Updated: February 26, 2010

Additional relevant MeSH terms:
Neuroendocrine Tumors
Carcinoid Tumor
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Neoplasms, Glandular and Epithelial processed this record on August 18, 2017